TABLE 5.
Difference in nonreactivity rates by varying cutoff points of induration to DTH testing with tetanus, mumps, and candida antigens among adolescent subjects by clinical statusa
| Cutoff points (mm) | No. (%) of subjects nonreactive to antigenb at indicated clinical stage
|
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Tetanus
|
Mumps
|
Candida
|
|||||||
| E | I | A | E | I | A | E | I | A | |
| 1 | 34 (38.6) | 12 (44.4) | 6 (85.7)c | 36 (40.9) | 9 (33.3) | 2 (28.6) | 10 (11.4) | 2 (7.4) | 2 (28.6) |
| 2 | 34 (38.6) | 12 (44.4) | 6 (85.7)c | 37 (42.0) | 10 (37.0) | 2 (28.6) | 11 (12.5) | 2 (7.4) | 2 (28.6) |
| 3 | 39 (44.3) | 14 (51.9) | 6 (85.7) | 43 (48.9) | 11 (40.7) | 2 (28.6) | 13 (14.8) | 2 (7.4) | 2 (28.6) |
| 4 | 44 (50.0) | 14 (51.9) | 6 (85.7) | 48 (54.5) | 16 (59.3) | 2 (28.6) | 15 (17.0) | 3 (11.1) | 2 (28.6) |
| 5 | 47 (53.4) | 15 (55.6) | 6 (85.7) | 51 (58.0) | 19 (70.4) | 3 (42.9) | 17 (19.3) | 4 (14.8) | 2 (28.6) |
a
Clinical status was defined as early (E) (n = 88), intermediate (I) (n = 27), or advanced (A) (n = 7).
b
For antigenic comparisons, subjects were more reactive to candida antigen than to tetanus or mumps antigen at all cutoff points (in early and intermediate stages only, P < 0.0001).
c
Only clinical category comparison nonreactivity rates significantly different for any antigen.